je.st
news
Tag: immunotherapy
New Kits, Proteins, And Screening Services For Immunotherapy Drug Discovery From BPS Bioscience
2014-06-04 12:15:09| drugdiscoveryonline Home Page
Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response
Tags: services
drug
discovery
screening
FDA Approves Mercks RAGWITEK (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
2014-04-18 00:22:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Robert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: without
short
treat
adults
FDA Approves Mercks GRASTEK (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults
2014-04-14 23:59:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved GRASTEK (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)]. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: without
children
treat
adults
Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014
2014-04-06 16:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Exploratory Analyses in Advanced Melanoma and NSCLC Presented in Oral Session Dr. Roger Perlmutter to Present at AACR Opening Plenary Session WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early findings from studies exploring the relationship between tumor PD-L1 expression and clinical outcomes following monotherapy treatment with MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma and advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: early
presented
meeting
annual
FDA OKs 1st dissolving immunotherapy tablet for seasonal allergies; 2 from Merck ...
2014-04-02 17:51:17| Biotech - Topix.net
The U.S. Food and Drug Administration has approved the first tablet for gradually reducing hay fever allergy symptoms, an alternative to uncomfortable allergy-desensitizing shots.
Tags: from
1st
seasonal
tablet